Michael Fitzgerald, LLB LLM

Non-Executive Chairman,

Member of remuneration committee

Michael is the founder of the Cloverleaf Group and is primarily focused on sourcing new investment opportunities as well as chairing many of the Cloverleaf Group’s existing investments, particularly those based in Europe. Michael also specialises in the structuring and financing of innovative technology and healthcare companies and in the provision of international banking and corporate legal services to clients in Australia, the United States and the United Kingdom. In 1995, Michael co-founded Gemini Genomics plc (Nasdaq: GMNI) and from 1995 to 2001 he served as Chairman and representative of the lead shareholder. Gemini was successfully merged with Sequenom, Inc. (Nasdaq: SQNM) in September 2001 in a transaction which valued Gemini at $238 million. Most recently, Michael co-founded and acts or acted as Chairman of each of Block Shield Corporation plc, Medcenter Holdings Inc., Quadrant Technologies Limited and Zenergy Power plc and is a director of Clear Play International Inc. and Roxro Pharma Inc. Michael has a Masters in Law and is admitted as a barrister in England and Wales, a barrister and solicitor in Victoria, Australia and a solicitor in New South Wales, Australia. He has authored numerous papers on company and banking law.